Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes

Boehringer Ingelheim

Status and phase

Terminated

Phase 1

Conditions

Myelodysplastic Syndromes

Treatments

Drug: Azacitidine

Drug: Volasertib

Study type

Interventional

Funder types

Industry

Identifiers

NCT02721875

2015-004490-32 (EudraCT Number)

1230.43

Details and patient eligibility

About

The objectives of this trial are to evaluate the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics and preliminary efficacy of volasertib in two dosing schedules of intravenous volasertib as monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome (MDS) after hypomethylating agents (HMA) treatment failure.

Enrollment

1 patient

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients 18 years and older with diagnosis of WHO classification-defined primary or treatment-related myeloid neoplasms classified as follows:
Refractory anaemia with excess blasts (RAEB)-1 (5%-9% marrow blasts) or
RAEB-2 (10%-19% marrow blasts or 5% - 19% peripheral blast) or
Chronic Myelomonocytic Leukaemia (CMML) (5%-19% blasts) with white blood cell (WBC) count <13000/mm3 or
Acute Myeloid Leukaemia (AML) (20%-29% marrow blasts, i.e., RAEB-t according to French-American-British [FAB] classification) with WBC count <10000/mm3
Patients classified as intermediate, high or very high-risk according to Revised - International Prognostic Scoring System (IPSS-R) at the time of enrolment
Patients who have received a maximum of 24 cycles of frontline HMA treatment prior to enrolment.
Patients must have received a minimum prior dosing schedule of either:
Azacitidine 75 mg/m2 x 5 days per cycle or 50 mg/m2 x 7 days per cycle, or
Decitabine 20 mg/m2 x 5 days per cycle, or
SGI-110 60 mg/m2 x 5 days per cycle
Patients must meet either one of the following criteria:
Progressive disease (PD, according to 2006 International Working Group (IWG) criteria) at any time after initiation of the prior HMA treatment, or
Relapse after initial complete (CR) or partial remission (PR) or haematological improvement (HI) (according to 2006 IWG criteria); or
Failure to achieve complete or partial remission or HI (according to 2006 IWG) with no evidence of progression (i.e., Stable Disease [SD]) after at least six cycles of prior azacitidine treatment or at least four cycles of other prior HMA treatment.
Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 at screening
Signed written informed consent consistent with International Conference of Harmonization Good Clinical Practice (ICH-GCP) and local legislation

Exclusion criteria

Prior systemic therapy (including investigational drugs) for MDS, CMML or AML within 14 days before treatment with study medication.
Patients requiring intervention for white blood cell count control with hydroxyurea, chemotherapy, or leukapheresis.
Prior exposure to more than one line of HMA based treatment.
Prior exposure to volasertib or other polo-kinase inhibitors
Patients who were unable to tolerate prior HMA treatment
Patients with history of hematopoietic stem cell transplant (HSCT)
Known hypersensitivity to the trial drugs or its excipients
Second malignancy currently requiring active therapy (except for hormonal/anti-hormonal treatment, e.g., in prostate or breast cancer).
QTcF value >470 ms or QT prolongation deemed clinically relevant by the investigator (e.g., congenital long QT syndrome).